MedVax Technologies, Inc., a Biopharmaceutical Company Developing and Commercializing Cancer Vaccine Immunotherapies, Announced Today its Founder and CEO will Attend BIO-Europe 2014
MIAMI, FL - November 12, 2014 - MedVax Technologies, Inc. announced today, Founder and Chief Executive Officer, Robert K. Brooks, will attend the 20th annual BIO-Europe 2014 conference taking place at the Portalhaus Messe Frankfurt conference center on November 3 - 5. The networking conference attracts a worldwide attendance from 60 countries with 3,000 delegates, representing 1,800 companies in the healthcare and finance industries. The conference features company presentations, workshops, exhibitions and high-level, face-to-face meetings with top industry leaders.
About MedVax Technologies,Inc.
MedVax (www.medvax.net) is a clinical-stage biopharrnaceutical company focused on developing cancer vaccine immunotherapies. The Company is developing two lead products of cancer vaccines, focused on Antigen Presenting Cells (APC's) of the immune system. MX-225 is anautologous P53 dendritic cell vaccine that recently completed PhaseII (a) clinical trials in Small Cell Lung Cancer and an ongoing Phase II trial in Breast Cancer at Moffitt Cancer Center. MX-402 is an on-autologous "off-the-shelf" HER-2 Peptide vaccine currently completing a 2nd PhaseI clinical trial in solid tumors at the James Cancer Center, Ohio State University.
Forward Looking Statement
This press release contains forward-looking statements,within the meaning of Section21E of the Securities Exchange Act of 1934 that reflect MedVax's current expectations about its future results,performance, prospects and opportunities.Where possible, MedVax has tried to identify these forward-looking statements by using words such as "anticipates", "believes", "intends", or similar expressions. These statements are subject to a number of risks,uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements.MedVax cannot assure you that it will be able to successfully develop or commercialize these products or its business strategy will be successful. MedVax assumes no obligation to update or revise any forward-looking statements as are result of new information, future events, changes in circumstances or for any other reason.
VP, Business Administration & Public Relations
MedVax Technologies, Inc.
Office: (305) 371-2301
Fax: (305) 371-2304
Source: MedVax Technologies, Inc.